GPCR 240816 22.50P (GPCR240816P22500) Stock Options, News & Quotes

0.60
0.000.00%

15min DelayTrading Jul 17 14:44 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Meltyy

Jul 17 22:40

Smid-cap obesity stocks hit by $RHHBY positive Ph1 data for oral GLP-1 obesity drug ⚠️

$ROCHE HOLDING AG(RHHBY.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US)$ $Novo-Nordisk A/S(NVO.US)$ $Structure Therapeutics(GPCR.US)$ $Viking Therapeutics(VKTX.US)$ $Lipocine(LPCN.US)$

frankinglily

Jul 12 03:26

Is the diet pill market too profitable to lose?

Why do you think $Pfizer(PFE.US)$ decided to progress with Danuglipron? (Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US)$ Orforglipron and $Structure Therapeutics(GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA

Hashtags

Jun 17 07:49

It seems that they will be going for acquisition of easy to manufacture weight loss pills $Structure Therapeutics(GPCR.US)$

USA faces the most severe drug shortage in a decade, with low stock price drugs and weight loss drugs becoming "disaster zones".

NinjaTradez

Jun 3 21:42

Tradershub.ninja

$Avalon GloboCare(ALBT.US)$ $Affimed NV(AFMD.US)$ $Structure Therapeutics(GPCR.US)$ $Finch Therapeutics(FNCH.US)$
On fire

mad541

Jun 3 15:00

News offering dropped🤢 ❗️❗️❗️**FOR IMMEDIATE RELEASE** Globe wire newsletter June 3,2024 2:57 pm est
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...